louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05862415: Concurrent Training for Optimal Physiological and Physical Benefits
Official title: Impact of Two Types of Concurrent Training for Optimal Physiological and Physical Benefits in Middle-Aged Adults: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Physical Inactivity
Keywords: Anaerobic work
Endurance
Aerobic training
Concurrent Training
Lead sponsor: Princess Nourah Bint Abdulrahman University
Sponsor class: OTHER
First posted: 2023-05-17
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is widely accepted that aerobic exercise and strengthen training are the core components of most workout programs. However, there is no clear consensus on whether the order in which the exercises are performed impacts their effectiveness. Therefore, the overarching aim of the study is to understand the optimal order of two types of concurrent training program for 13 weeks by comparing the effectiveness of the training on body composition, predicated maximal oxygen uptake (MaxVO2), dynamic respiratory parameters, and muscle strength in healthy middle-aged people. Methods:Thirty-three moderately-active middle-aged and healthy participants were randomly assigned to the strength+aerobic group (SAG, n = 16) and aerobic+strength group (ASG, n = 17). Body composition, aerobic endurance, respiratory parameters and upper and lower strength were assessed before (pre-test) and after (post-test) a 13-week intervention. The chi-square test and the independent t-test will be used to compare sociodemographic variables between the groups. A 2 x 2 analysis of variance (ANOVA) with repeated measures (group x measurement) will be conducted.

This study will enhance our understanding of the concurrent training effect on muscle composition and strength. These training programs allow for reducing the duration of the training, which can be an important factor in making adults more willing to participate in physical activity.


Eligibility criteria: Inclusion Criteria:

* middle-aged adults ( over the age of 40)
* No history of cardiovascular or neuromuscular disorders
* not having orthopedic disorder or neurologic disorders.

Exclusion Criteria:

* adults using artificial prosthesis
* participation in any structured training program
* any disease that precludes exercise or necessitates special care (for example, coronary artery disease, thrombosis, moderate or severe bone disease, and lung or renal disease)

Primary outcomes:
measure: Body fat %
timeFrame: 10 min
measure: Predicated maximal oxygen uptake (MaxVO2)
timeFrame: 1 day
measure: Forced Vital Capacity (FVC)
timeFrame: 1 day
measure: Forced Expiratory Volume in One Second
timeFrame: 1 day
measure: Grip Strength
timeFrame: 1 day
measure: 1-Repetition Maximum Strength
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: Princess Nourah bint Abdulrahman University
Study officials:
References:
Clinical trial NCT00168415: A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hyperhidrosis
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2005-09-15
Enrollment: 144
Sex: ALL
Minimum age (years): 12
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A study using Botulinum Toxin Type A in adolescents with axillary hyperhidrosis.


Eligibility criteria: Inclusion Criteria:

* Marked axillary hyperhidrosis

Exclusion Criteria:

* Previous use of botulinum toxin for hyperhidrosis

Primary outcomes:
measure: Subject's assessment of the severity of hyperhidrosis using the HDS Scale
timeFrame: Monthly
Secondary outcomes:
measure: Measurement of axillary sweat production
timeFrame: Week 4, Week 8 and any re-injection visit
Other outcomes:
Locations:
city: Portland
country: United States
state: Oregon
city: Vancouver
country: Canada
state: British Columbia
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Glaser DA, Pariser DM, Hebert AA, Landells I, Somogyi C, Weng E, Brin MF, Beddingfield F. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis. Pediatr Dermatol. 2015 Sep-Oct;32(5):609-17. doi: 10.1111/pde.12620. Epub 2015 Jun 8.
Clinical trial NCT01477515: Endocannabinoids in End Stage Renal Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: End Stage Renal Disease
Nutrition
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2011-11-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Hemodialysis patients healthy control subjects

Brief summary: To investigate the relationship between dietary intake, body habitus, and endocannabinoid levels in end stage renal disease patients as compared to matched controls.


Eligibility criteria: Inclusion Criteria:

* hemodialysis patient, able to give informed consent

Exclusion Criteria:

* hospitalization in past 3 months

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04035915: Comparison Between Limited Driving Pressure Ventilation and Conventional Mechanical Ventilation Strategies in Medical Intensive Care Patients With Acute Respiratory Failure
Official title: Comparison Between Limited Driving Pressure Ventilation and Conventional Mechanical Ventilation Strategies in Medical Intensive Care Patients With Acute Respiratory Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: on Invasive Mechanical Ventilation
ARDS
Respiratory Failure
Keywords: Limited driving pressure
Low tidal volume
Lung injury score
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2019-07-29
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background An appropriated mechanical ventilator setting for acute respiratory failure results of ventilator associated lung injury. Limited driving pressure and low tidal volume ventilation strategies show benefits decreasing mortality in acute respiratory distress syndrome, but there are no data in simple acute respiratory failure.

Detailed description: Background An appropriated mechanical ventilator setting for acute respiratory failure results of ventilator associated lung injury. Limited driving pressure and low tidal volume ventilation strategies show benefits decreasing mortality in acute respiratory distress syndrome, but there are no data in simple acute respiratory failure.

To compare lung injury score (LIS, Murray score) after invasive mechanical ventilation 7 days between groups of limited driving pressure ventilation versus low tidal volume ventilation strategies.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 year old MICU patient
* On Invasive mechanical ventilator less than 24 hr. before randomization

Exclusion Criteria:

* Suspected death within 48 hr. after randomization
* patients with tracheostomy tube
* Pregnancy
* Do not attempt resuscitation order
* Patient with ECMO before randomization

Primary outcomes:
measure: Lung injury score
timeFrame: Day 7 after invasive mechanical ventilation
Secondary outcomes:
measure: 28 days Mortality
timeFrame: Upto 28 days
measure: New onset of ARDS
timeFrame: Upto 28 days
Other outcomes:
Locations:
city: Bangkok Noi
country: Thailand
facility: Mahidol university
state: Bangkok
Study officials:
affiliation: Mahidol University
name: Surat Tongyoo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05723315: Effect of rhBNP on CMD in Patients With STEMI After PPCI
Official title: Effect of rhBNP on Coronary Microcirculation in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: STEMI
Lead sponsor: Henan Institute of Cardiovascular Epidemiology
Sponsor class: OTHER
First posted: 2023-02-10
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The target population of this interventional study was STEMI patients. Primary discussion: Early rhBNP reduces microcirculation obstruction in STEMI patients undergoing primary PCI

Detailed description: Direct percutaneous coronary intervention is the preferred reperfusion strategy for acute ST-segment elevation myocardial infarction. During the opening of infarct-related vessels, 5%-50% of patients showed slow flow or no reflow and other coronary microcirculation dysfunction, which aggravated myocardial injury and increased the incidence and mortality of heart failure. Studies have shown that recombinant human brain natriuretic peptide (rhBNP) can reduce reperfusion injury and reduce myocardial infarction area CMD. Prolonged ischemia leads to rapid depletion of intracellular ATP and tissue metabolic acidosis. Blood flow irrigation during reperfusion leads to decreased levels of ATP precursors, calcium overload in mitochondria, release of a large number of inflammatory factors and oxygen free radicals, which can lead to injury or death of myocardial and endothelial cells. rhBNP can enhance the activity of antioxidant enzymes, reduce the irreversible oxidative damage caused by free radicals to myocardium, reduce the myocardial infarction area during ischemia reperfusion, and may reduce the reperfusion injury and protect the viable myocardium.

Eligibility criteria: Inclusion Criteria:

* STEMI
* PPCI within 24 hours of symptom onset
* Target vessel QFR-MR\>250mm Hg\*s/m

Exclusion Criteria:

* claustrophobia
* Postoperative TIMI grade 0-1
* Pregnancy

Primary outcomes:
measure: MVO/LV(%)
timeFrame: 3-14 days after PPCI
Secondary outcomes:
measure: LGE/LV(%)
timeFrame: 3-14 days and 90±7 days after PPCI
measure: IMH
timeFrame: 3-14 days after PPCI
measure: MVO/LV(%)
timeFrame: 30±7 days after PPCI
measure: LVEDV(ml)
timeFrame: 3-14 days and 90±7 days after PPCI
measure: LVESV(ml)
timeFrame: 3-14 days and 90±7 days after PPCI
measure: Troponin (highest value)
timeFrame: 3-14 days after PPCI
measure: MACCEs
timeFrame: 7days，30days，3months，6 months
Other outcomes:
Locations:
Study officials:
affiliation: Fuwai central China cardiovascular hospotial
name: Muwei Li, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02901015: Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning
Official title: Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning (EVACO)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Keywords: schizophrenia
Lead sponsor: Versailles Hospital
Sponsor class: OTHER
First posted: 2016-09-15
Enrollment: 173
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Interventional, multicenter, and longitudinal study, of a cohort of patients with schizophrenia, evaluated on social cognition, neurocognition, symptoms, functioning with 12 months interval.

Detailed description: The main objective is evaluation and validation of social cognition battery, characterizing the psychometric properties (validity, sensitivity to change) measures in a cohort of schizophrenic patients. Other objective is to demonstrate that the various components operating at T0 and T12 months of schizophrenic patients, as an external validator, are significantly explained by social cognition performance given the third known factors : neuropsychological, sociodemographic, disease course, and clinical status. Search and model relationships between the measured variables.

Eligibility criteria: Inclusion Criteria:

* Schizophrenia or schizoaffective disorder
* Age \> 18 years and \< 65 years
* Patient's state allows cognitive and neuropsychological assessment
* Affiliated to a social security system (beneficiary or legal).
* Informed consent signature (patients under guardianship may be included with written permission from their legal representative).

Exclusion Criteria:

* Alcohol dependence or current toxic
* Electroconvulsivotherapy (less than 6 months)
* Serious head trauma (become unconscious), epilepsy or neurological disorder significant or evolutionary
* Invalidating and uncorrected visual disorder
* Invalidating and not paired hearing
* Actually hospitalized under constraint
* Patient not able to come to different evaluations, or who plan to change medical care in the following year

Primary outcomes:
measure: Change in cognitive skills
timeFrame: Day 0, Month 12
Secondary outcomes:
measure: Change in Functioning
timeFrame: Day 0, Month 12
measure: Change in Psychotic symptoms
timeFrame: Day 0, Month 12
Other outcomes:
Locations:
city: Clermont Ferrand
country: France
facility: CHU de Clermont Ferrand
city: Colombes
country: France
facility: Hôpital Louis Mourier
city: Créteil
country: France
facility: Hôpital Henri Mondor
city: Le Chesnay
country: France
facility: Centre Hospitalier de Versailles
city: Marseille
country: France
facility: Hôpital Sainte Marguerite
city: Montpellier
country: France
facility: CHRU de Montpellier
city: Saint Egrève
country: France
facility: Centre Hospitalier Alpes Isère
city: Strasbourg
country: France
facility: CHU de Strasbourg
Study officials:
References:
Clinical trial NCT06901115: Corkscrew Technique: A Novel Modification in Transurethral Resection of Large Prostate (60-100 g) Optimizing Resection Efficacy and Safety: A Double-blind Randomized Controlled Trial
Official title: Corkscrew Technique: A Novel Modification in Transurethral Resection of Large Prostate (60-100 g) Optimizing Resection Efficacy and Safety: A Double-blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: TURP(Transurethral Resection of Prostate)
BPH (Benign Prostatic Hyperplasia)
Prostate
Keywords: TURP
BPH
Prostate
Blandy
Nesbit
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2025-03-28
Enrollment: 90
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Transurethral resection of the prostate (TURP) is still the gold standard for surgical management of enlarged prostate. However, many techniques and minimally invasive procedures are now in the comparative track with Bipolar resection as Laser enucleation.

Multiple drawbacks of Classic TURP problems related to large prostate management as the retreatment after Bipolar resection, another issue that prolonged operative time, Loss of orientation during resection due to rotation of one of the 2 kissing lobe, Bleeding of the 1st lobe resection side make the 2nd lobe resection harder and lengthier, Median lobe resection or bladder neck resection is done at last to avoid sub-trigonal injury. however, due to median lobe obstruction, irrigation is poor during all the resection. length of learning curve, the modification of early median lobe resection carry the risk of sub-trigonal injury.

So, this study is a trial to analyze the effect of new technique in resection of large prostate with good orientation and less time of operation.


Eligibility criteria: Inclusion Criteria:

* BPH causing LUTS with prostate volume between 60 and 100 ml (either by TRUS or CT).
* PSA level below 4 ng/ml.
* IPSS score of 10 and above.

Exclusion Criteria:

* previous history of prostatic biopsy.
* previous history of acute urinary retention.

Primary outcomes:
measure: Weight of resected tissue
timeFrame: within one hour postoperatively
measure: Resection time
timeFrame: the operative time
measure: Complication rate
timeFrame: the operative time
Secondary outcomes:
measure: Change in International Prostate symptom score (IPSS)
timeFrame: one month postoperatively
measure: Change in Qmax
timeFrame: One month postoperatively
measure: Change in postvoid residual volume
timeFrame: One month postoperatively
measure: Change in hemoglobin level
timeFrame: One day postoperatively
Other outcomes:
Locations:
city: Shebin El-Kom
country: Egypt
facility: Menoufia Faculty of Medicine
state: Menoufia
Study officials:
References:
Clinical trial NCT05537415: Prevalence of Medical Care in an Emergency Structure of the Women Victims of Violence Within the Couple
Official title: Prevalence of Medical Care in an Emergency Structure and Expectations Vis-à-vis the Care System Among Women Victims of Violence Within the Couple Treated in the Associative, Social and Medico-legal Environment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Spousal-Abuse
Keywords: Spousal-Abuse
Violence against women
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2022-09-13
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult women (age ≥ 18 years old) victims of violence committed within the couple

Brief summary: Violence against women within the couple is a major socio-political and public health problem.

Indeed, in 2020, 219,000 women were victims of violence within their couple and 102 women were killed by their partner or ex-partner.

On average, the number of women aged 18 to 75 who in the course of a year are victims of rape and/or attempted rape is estimated at 94,000 women, and in 47% of cases it is the spouse or the ex-spouse who is the author of the facts.

This violence has major health and social consequences: the leading cause of death and disability among women aged 16 to 44 in Europe. In France, a woman dies as a result of domestic violence every 2.5 days and the overall cost of domestic violence in 2012 amounted to 3.6 billion euros in France.

A better knowledge of the use of care for wives of victims of violence and their feelings vis-à-vis the medical care in an emergency service will make it possible to identify the problems related to their care based on their feelings. of these patients, to understand why they would not have consulted as a first resort if necessary and to subsequently propose avenues for improvement.


Eligibility criteria: Inclusion Criteria:

* Adult women (age ≥ 18 years old)
* victims of violence committed within the couple
* Initial visit to the emergency room or not
* Subject not opposed to participating in the study

Exclusion Criteria:

* Intra-family violence committed by a parent, outside the couple (for example: father, grandfather, brother, cousin, uncle, child)
* Impossibility of giving informed information to the subject (subject in an emergency situation, difficulties in understanding the subject, etc.)

Primary outcomes:
measure: Prevalence of recourse to care in an emergency structure among women cared for in a reception center for women victims of violence
timeFrame: from January 01, 2012 to December 31, 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'accueil des urgences - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT03145415: Comparison of Pudendal Nerve Block and Caudal Block for Hypospadias in Young Children
Official title: Comparison of Pudendal Nerve Block vs Caudal Block for Hypospadias Repair in Young Children: A Blinded Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypospadias and Epispadias
Keywords: pudendal nerve block
hypospadias
caudal block
Lead sponsor: Nemours Children's Clinic
Sponsor class: OTHER
First posted: 2017-05-09
Enrollment: 60
Sex: MALE
Minimum age (years): 6
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: All Children will be randomly assigned to one of 2 groups of 30 patients each using a computer generated number table.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this randomized blinded prospective study is to compare the analgesic efficacy and duration of a Pudendal Nerve Block (PNB) to a Caudal Block (CB) for pediatric patients, ages 6 months to 2 years, undergoing hypospadias repair.

Detailed description: Hypospadias repair is one of the most common congenital malformations of the penis in the United States. It has an incidence of about 1 in 300 births. A combination of general anesthesia and a caudal block or general anesthesia combined with a pudendal nerve block are commonly used for hypospadias repair.

In our institution, hypospadias repair is typically done in infants and children ages 6 months to age two. A comparison of the efficacy of pudendal block versus the caudal block has not been undertaken in this younger population.

Eligibility criteria: Inclusion Criteria:

* Boys undergoing hypospadias repair

Exclusion Criteria:

-

Primary outcomes:
measure: Opioid consumption
timeFrame: up to 24 hours
Secondary outcomes:
measure: Intraoperative block assessment
timeFrame: up to 3 hours
measure: Post operative pain
timeFrame: up to 2 hours
Other outcomes:
Locations:
city: Wilmington
country: United States
facility: Nemours/ duPont Hospital for Children
state: Delaware
Study officials:
References:
citation: Choudhry DK, Heredia L, Brenn BR, Brown M, Carvalho NF, Whaley MC, Shaik SS, Hagerty JA, Bani Hani A. Nerve stimulation guided bilateral pudendal nerve block versus landmark-based caudal block for hypospadias repair in young children: a prospective, randomized, pragmatic trial. Reg Anesth Pain Med. 2022 Dec;47(12):744-748. doi: 10.1136/rapm-2022-103680. Epub 2022 Sep 8.
Clinical trial NCT01239615: Test-retest Stability of MR-parameters. A Neuroimaging Pilot-study in Healthy Volunteers
Official title: Test-retest Stability of MR-parameters. A Neuroimaging Pilot-study in Healthy Volunteer
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Magnetic Resonance
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2010-11-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Sampling method: PROBABILITY_SAMPLE
Study population: healthy volunteers

Brief summary: Aim: To study the stability of brain MR-scanning parameters (blood-flow, microstructure, volume, metabolism) over 1 week in health volunteers.

Hypothesis: MR-scanning parameters are stable over 1 week in healthy volunteers


Eligibility criteria: Inclusion Criteria:

* age 18-65
* oral and written consent

Exclusion Criteria:

* intracranial disease
* previous intracranial surgery
* magnetic implant or magnetic foreign body
* claustrophobia

Primary outcomes:
measure: cortical volume/thickness
Secondary outcomes:
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Aalborg Hospital
Study officials:
References: